Akari Therapeutics (NASDAQ:AKTX) versus Innate Pharma (NASDAQ:IPHA) Critical Analysis

Innate Pharma (NASDAQ:IPHA) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Innate Pharma and Akari Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1	0	5	0	2.67
Akari Therapeutics	1	0	3	0	2.50

Innate Pharma presently has a consensus target price of $6.67, indicating a potential upside of 200.30%. Akari Therapeutics has a consensus target price of $32.33, indicating a potential upside of 324.32%. Given Akari Therapeutics’ higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than Innate Pharma.

Profitability

This table compares Innate Pharma and Akari Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Akari Therapeutics	N/A	-147.45%	-74.70%

Earnings & Valuation

This table compares Innate Pharma and Akari Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79 million	74.81	-$55.64 million	N/A	N/A
Akari Therapeutics	N/A	N/A	-$17.30 million	N/A	N/A

Akari Therapeutics has lower revenue, but higher earnings than Innate Pharma.

Risk & Volatility

Innate Pharma has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Insider & Institutional Ownership

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.